Patents by Inventor Meenhard Herlyn

Meenhard Herlyn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190276517
    Abstract: Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.
    Type: Application
    Filed: February 16, 2017
    Publication date: September 12, 2019
    Inventors: Rajasekharan Somasundaram, Meenhard Herlyn, Dorothee Herlyn
  • Publication number: 20180228740
    Abstract: Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.
    Type: Application
    Filed: August 5, 2016
    Publication date: August 16, 2018
    Inventors: Gao Zhang, Qin Liu, Dario Carlo Altieri, Meenhard Herlyn
  • Publication number: 20150166646
    Abstract: Methods and compositions are provided for treating melanoma in a mammalian subject by reducing, inhibiting or down-regulating tumor-associated macrophage (TAM) production or activity in the subject. The methods can involve a combination of reducing macrophage production and number while administering an anti-cancer therapy. The treatment can involve the combined blocking or down-regulating of the nucleic acid or protein expression or activity, or the downstream pathway of CCL-2; with the blocking or down-regulating of the nucleic acid or protein expression or activity, or the downstream pathway of a matrix metalloprotease (e.g., MMP9). Another aspect involves blocking the expression or activity of VEGF. Another aspect involves blocking or down-regulating the expression, activity or signaling of the MAPK pathway or the PI3K-AKT-mTOR pathway.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 18, 2015
    Inventors: Tao Wang, Meenhard Herlyn, Russel E. Kaufman
  • Patent number: 8999706
    Abstract: Isolated human multipotent adult stem cell and isolated populations of cells that include human multipotent adult stem cells are disclosed. Human hair-follicle derived multipotent adult stem cells and methods of preparing isolated populations of cells that include human multipotent adult stem cells are disclosed. Isolated human hair-follicle derived multipotent adult stem cell that can differentiate in culture into a neuronal cell, a glial cell, a melanocyte cell, a muscle cell, an osteocyte, a chondrocyte, and a lymphocyte. Isolated human hair-follicle derived multipotent adult stem cell that can grow in cell culture in spheres are disclosed.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: April 7, 2015
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology
    Inventors: Xiaowei Xu, Hong Yu, Douglas Dong Fang, Meenhard Herlyn
  • Publication number: 20120164148
    Abstract: The present invention features compositions and methods for treating cancers such as melanoma, which have a subpopulation of self-renewing JARIDIB-positive cells essential to maintenance and metastatic progression of the cancer.
    Type: Application
    Filed: August 6, 2010
    Publication date: June 28, 2012
    Applicant: The Wistar Institute
    Inventors: Alexander O. Roesch, Meenhard Herlyn
  • Publication number: 20110177042
    Abstract: The present invention features a method for producing a dedifferentiated melanocyte. The method involves contacting a melanocyte with an agent that activates Notch1 and selecting for a dedifferentiated melanocyte which exhibits a premelanoma stem cell-like state. Agents for activating Notch1 and methods for using the cells and agents are also provided.
    Type: Application
    Filed: September 30, 2009
    Publication date: July 21, 2011
    Inventors: Meenhard Herlyn, Susan E. Zabierowski
  • Patent number: 7544465
    Abstract: A three-dimensional reconstruct model containing solid layers of collagen and fibroblasts closely mimic the condition of patients in vivo, preserving in vivo phenotypic and functional characteristics of the cells. Reconstructs can be used to detect cellular migration, including active migration of cytotoxic T lymphocytes towards tumor cells, which can be measured by detecting tumor cell lysis. Reconstructs also can be used to identify factors that influence migration of cells, including chemokines that influence migration of cytotoxic T lymphocytes, as well as to identify tumor antigens.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: June 9, 2009
    Assignee: The Wistar Institute
    Inventors: Dorothee Herlyn, Meenhard Herlyn, Rajasckharan Somasundaram
  • Publication number: 20090130065
    Abstract: Isolated human multipotent adult stem cell and isolated populations of cells that include human multipotent adult stem cells are disclosed. Human hair-follicle derived multipotent adult stem cells and methods of preparing isolated populations of cells that include human multipotent adult stem cells are disclosed. Isolated human hair-follicle derived multipotent adult stem cell that can differentiate in culture into a neuronal cell, a glial cell, a melanocyte cell, a muscle cell, an osteocyte, a chondrocyte, and a lymphocyte. Isolated human hair-follicle derived multipotent adult stem cell that can grow in cell culture in spheres are disclosed.
    Type: Application
    Filed: April 12, 2006
    Publication date: May 21, 2009
    Inventors: Xiaowei Xu, Hong Yu, Douglas Dong Fang, Meenhard Herlyn
  • Patent number: 7217570
    Abstract: An organotypic culture comprises an artificial stroma overlayed with epithelial cells isolated from a human colon or intestine. The stroma comprises a mixture of collagen and human fibroblasts isolated from a human colon or intestine. The culture contains a factor that binds the IGF-1 receptor, a factor that binds the EGF receptor, and a factor that binds the LIF receptor. These factors may be added exogenously to the culture via medium or may be expressed by various recombinantly engineered cell types in the culture. The organotypic culture can result in growth that is in situ-like or emphasizes other physiological or morphological states, depending on the balance of factors in the growth media. The organotypic culture may be used in methods for screening of therapeutic, carcinogenic, or growth enhancement factors, or for treating intestinal injuries by applying to the site of an injury the intact culture or the components thereof.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: May 15, 2007
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Meenhard Herlyn, Jiri Kalabis
  • Publication number: 20060073469
    Abstract: A three-dimensional reconstruct model containing solid layers of collagen and fibroblasts closely mimic the condition of patients in vivo, preserving in vivo phenotypic and functional characteristics of the cells. Reconstructs can be used to detect cellular migration, including active migration of cytotoxic T lymphocytes towards tumor cells, which can be measured by detecting tumor cell lysis.
    Type: Application
    Filed: September 27, 2002
    Publication date: April 6, 2006
    Inventors: Dorothee Herlyn, Meenhard Herlyn, Rajasckharan Somasundaram
  • Publication number: 20040175367
    Abstract: An organotypic culture comprises an artificial stroma overlayed with epithelial cells isolated from a human colon or intestine. The stroma comprises a mixture of collagen and human fibroblasts isolated from a human colon or intestine. The culture contains a factor that binds the IGF-1 receptor, a factor that binds the EGF receptor, and a factor that binds the LIF receptor. These factors may be added exogenously to the culture via medium or may be expressed by various recombinantly engineered cell types in the culture. The organotypic culture can result in growth that is in situ-like or emphasizes other physiological or morphological states, depending on the balance of factors in the growth media. The organotypic culture may be used in methods for screening of therapeutic, carcinogenic, or growth enhancement factors, or for treating intestinal injuries by applying to the site of an injury the intact culture or the components thereof.
    Type: Application
    Filed: January 29, 2004
    Publication date: September 9, 2004
    Inventors: Meenhard Herlyn, Jiri Kalabis
  • Publication number: 20040031067
    Abstract: The invention relates to new compositions and methods for preparing vascularized dermal reconstructs, vascularized skin grafts, and for enhancing vascularization in situ in response to a variety of medical conditions.
    Type: Application
    Filed: August 22, 2003
    Publication date: February 12, 2004
    Inventors: Meenhard Herlyn, Carola Berking, Kapaettu Satyamoorthy, Omaida Velazquez
  • Patent number: 6486133
    Abstract: A method for repairing defects and inducing vascularization in mammalian tissue, preferably skin, involves administering to the tissue a recombinant replication defective virus, preferably adenovirus, carrying a selected growth factor gene, preferably VEGF or PDGF, under operative control of regulatory sequences which direct the expression of the growth factor(s). Also provided is a method for infecting a tissue to be transplanted with such recombinant adenoviruses prior to transplantation and, as a composition, an infected culture of human tissue to be transplanted which is infused with a selected growth factor prior to transplantation. Screening methods for the treatment of angiogenic disorders, e.g., hemangiomas and cancers, also employ an animal model on which is engrafted a full thickness human tissue infused with a growth factor.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: November 26, 2002
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Meenhard Herlyn, Mark Nesbit, Kapaettu Satyamoorthy
  • Publication number: 20020165188
    Abstract: The present invention provides a method for preventing proliferation of melanoma cells by contacting melanoma cells with an agent which is capable of modulating the expression of E-cadherin in the melanoma cells thereby restoring keratinocyte control over melanoma cell proliferation.
    Type: Application
    Filed: January 30, 2002
    Publication date: November 7, 2002
    Inventors: Meenhard Herlyn, Kapaettu Satyamoorthy
  • Publication number: 20020081711
    Abstract: The invention includes compositions for inhibiting a phenotype associated with diseased cells in a mammal and compositions and methods for generating genetic suppressor elements for inhibiting such phenotypes. The invention further includes pharmaceutical compositions and methods of treatment for mammals (e.g. humans) afflicted with melanoma or other solid tumors.
    Type: Application
    Filed: September 28, 2001
    Publication date: June 27, 2002
    Applicant: The Wistar Institute
    Inventors: Meenhard Herlyn, Kapaettu Satyamoorthy
  • Patent number: 5633142
    Abstract: The present invention provides three unique monoclonal antibodies directed against a portion of the Wilms' tumor antigen, and methods of use therefor in detecting, monitoring and diagnosing malignancies characterized by over-expression or inappropriate expression of the WT 1 protein.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 27, 1997
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Meenhard Herlyn, Jennifer Morris, Frank J. Rauscher, III, Ulrich Rodeck
  • Patent number: 5622835
    Abstract: Three unique monoclonal antibodies, each having an epitope located in amino acids 1-181 of the WT1 tumor protein, and the hybridomas which secrete them have been constructed. These monoclonal antibodies are useful in the detection, monitoring, and diagnosis of malignancies characterized by inappropriate expression of the WT1 protein.
    Type: Grant
    Filed: April 28, 1994
    Date of Patent: April 22, 1997
    Assignee: The Wistar Institute of Anatomy & Biology
    Inventors: Meenhard Herlyn, Jennifer Morris, Frank J. Rauscher, III, Ulrich Rodeck
  • Patent number: 5470571
    Abstract: Monoclonal antibody 425 having properties particularly beneficial for anti-tumor therapy has been raised. MAb 425 antibody binds to EGF-receptors and inhibits their bioactivities. The amount of binding of the antibody to cancer cells can be increased by treatment of the cells with lymphokine preparations. Radiolabeled MAb 425 is used for treatment of EGF receptor-expressing gliomas.
    Type: Grant
    Filed: April 24, 1990
    Date of Patent: November 28, 1995
    Assignee: The Wistar Institute
    Inventors: Meenhard Herlyn, Ulrich Rodeck
  • Patent number: 4849509
    Abstract: The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are reactive with ganglioside antigens GD2 and GD3 and are essentially non-reactive with other ganglioside antigens. The invention further relates to methods of using these antibodies.
    Type: Grant
    Filed: February 20, 1987
    Date of Patent: July 18, 1989
    Assignee: The Wistar Institute
    Inventors: Jan Thurin, Hilary Koprowski, Meenhard Herlyn, Zenon Steplewski
  • Patent number: 4786593
    Abstract: It has been determined that nerve growth factor binds to a cell surface protein of human neural crest origin having a molecular weight of about 75,000 daltons. New monoclonal antibodies specifically imunoprecipitate these receptor molecules, and also inhibit binding of the hormone to the receptor. These monoclonal antibodies show significantly higher reactivity with primary and metastatic melanoma cell lines than with melanocytes. The antibodies are used in a diagnostic method for histochemical detection of human neural crest disease.
    Type: Grant
    Filed: April 16, 1985
    Date of Patent: November 22, 1988
    Assignee: Wistar Institute of Anatomy and Biology
    Inventors: Alonzo Ross, Hilary Koprowski, Meenhard Herlyn